FEATURES & BENEFITS
Cuttlefish Bio is overcoming the fundamental toxicity limitations of Antibody-Drug Conjugates (ADCs) through our precision-engineered ADEPT platform.
Engineered for Multi-Round Therapy
We have replaced immunogenic bacterial enzymes previously used in ADEPT approaches with computationally re-engineered human enzymes, allowing for safe, repeated treatment cycles.
Potency without Internalization
Unlike ADCs, our technology works in the extracellular space, removing the requirement for the cell to internalize the antibody to be effective. Because the activated payload is free to diffuse, it kills neighboring antigen-negative cells, effectively treating heterogeneous tumors.
Ease of Manufacturing
The ADE is a fusion protein which can be manufactured using existing infrastructure and does not require any post-translational chemistry.
Uncapped Potency
Traditional ADCs have a limited drug to antibody ratio. With ADEPT, a single enzyme can activate thousands of prodrug molecules per second, delivering payload concentrations that traditional ADCs simply cannot match.
Targeting the "Untreatable"
Ideal for tumours with dense stroma, like pancreatic cancer, where biologics struggle to penetrate but small-molecule payloads can diffuse rapidly.
Platform Versatility
A single enzyme can be paired with any tumor-targeting antibody and also activate different prodrugs.